Department of Plastic and Reconstructive Microsurgery, Careggi University Hospital, Florence, Italy.
Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, Florence, Italy.
Aesthetic Plast Surg. 2020 Jun;44(3):1006-1013. doi: 10.1007/s00266-020-01678-2. Epub 2020 Mar 20.
Transmen are individuals who live a marked incongruence between the assigned gender and the experienced gender. Crucial and life-changing steps in their transition are testosterone treatment and mastectomy to remove the stigma of feminine identity. After surgery, patients' attention turns to the scars, often not aesthetically pleasant. We thus created an innovative galenic preparation for scar treatment after surgery composed by spironolactone, alfa bisabolol and silicone gel. Functional outcomes, side effects and satisfaction were assessed.
For the present prospective randomized controlled study, 30 patients with similar demographic characteristics who underwent double incision mastectomy with NA grafts between February 2014 and June 2019 were selected. The treatment Group A (n = 15) was treated for 12 months with "Top Surgery Scar go," the control Group B (n = 15) with silicon gel. Statistical analysis including Wilcoxon test and Kruskal-Wallis test per variable was performed. To assess satisfaction, a second Wilcoxon test was applied.
The differences between Group A and Group B were statistically significant, especially at T12 with very low p values. Satisfaction was greater in Group A (p value = 3e-4). No major side effects were noticed in Group A.
TSSgo scar innovative treatment showed long-term efficacy in comparison with silicon gel in terms of improved scar tissue texture, pigmentation, pliability and height. It is easy to set up, cost-effective and safe. Further studies are necessary to better assess efficacy and validity of TSSgo, but it appears to be promising as the new treatment of reference for scar management after top surgery in transmen.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
跨性别男性是指在分配性别和体验性别之间存在明显不一致的个体。在他们的过渡过程中，关键且改变生活的步骤是接受睾丸激素治疗和乳房切除术，以去除女性身份的耻辱。手术后，患者的注意力转向疤痕，往往不美观。因此，我们开发了一种新的用于手术后疤痕治疗的制剂，由螺内酯、阿尔法- 胡萝卜素醇和硅凝胶组成。评估了功能结果、副作用和满意度。
本前瞻性随机对照研究选择了 2014 年 2 月至 2019 年 6 月期间接受双切口乳房切除术和 NA 移植物的 30 名具有相似人口统计学特征的患者。治疗组 A（n=15）接受“Top Surgery Scar go”治疗 12 个月，对照组 B（n=15）接受硅凝胶治疗。对每个变量进行了包括 Wilcoxon 检验和 Kruskal-Wallis 检验在内的统计分析。为了评估满意度，应用了第二次 Wilcoxon 检验。
组 A 和组 B 之间的差异具有统计学意义，尤其是 T12 时的 p 值非常低。组 A 的满意度更高（p 值=3e-4）。组 A 未发现重大副作用。
与硅凝胶相比，TSSgo 创新疤痕治疗在改善疤痕组织质地、色素沉着、柔韧性和高度方面具有长期疗效。它易于设置、具有成本效益且安全。需要进一步的研究来更好地评估 TSSgo 的疗效和有效性，但它似乎很有前途，是跨性别男性乳房手术后疤痕管理的新治疗参考。
证据等级 IV：本期刊要求作者为每篇文章指定一个证据等级。有关这些循证医学评级的完整描述，请参阅目录或在线作者指南 www.springer.com/00266。
